Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov 15;10(11):e6548.
doi: 10.1002/ccr3.6548. eCollection 2022 Nov.

Successful treatment of persistent and severe SARS-CoV-2 infection in a high-risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies

Fernanda Braga Seganfredo  1 , Ana Raquel Dias  2 , Pedro R Santos  3 , Marta Rebelo  3 , Cristina João  4 , Dina Mendes  5 , Eduarda Carmo  3
Affiliations
Case Reports

Successful treatment of persistent and severe SARS-CoV-2 infection in a high-risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies

Fernanda Braga Seganfredo et al. Clin Case Rep. .

Abstract

Patients with lymphoproliferative diseases are at an increased risk of an incomplete immune response following vaccination or SARS-CoV-2 infection and might develop persistent viral infection and severe COVID-19 disease. We present a case of successful treatment of persistent and mechanical-ventilation-requiring SARS-CoV-2 infection in a del17+ CLL patient using exogenous antibodies.

Keywords: COVID‐19; Casirivimab and Imdevimab; haemato‐oncological patients; immunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
CT scans showing SARS‐CoV‐2 pneumonia, with ground glass opacity and reticulation. This reticulation was extended to every lobe and affected >50% of both lungs.
FIGURE 2
FIGURE 2
CT scans showing worsening of the pulmonary infiltrates, patchy consolidations and subpleural sparing, suggesting progression to organizing pneumonia.
See this image and copyright information in PMC

References

    1. Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020;21(5):1825. doi:10.3390/ijms21051825 - DOI - PMC - PubMed
    1. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573‐581. doi:10.1182/blood-2015-03-567388 - DOI - PubMed
    1. Parikh SA, Shanafelt TD. Prognostic factors and risk stratification in chronic lymphocytic leukemia. Semin Oncol. 2016;43(2):233‐240. doi:10.1053/j.seminoncol.2016.02.009 - DOI - PubMed
    1. Chatzikonstantinou T, Kapetanakis A, Scarfò L, et al. COVID‐19 severity and mortality in patients with CLL: an update of the international ERIC and campus CLL study. Leukemia. 2021;35:3444‐3454. doi:10.1038/s41375-021-01450-8 - DOI - PMC - PubMed
    1. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID‐19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134‐1143. doi:10.1182/blood.2020006965 - DOI - PMC - PubMed

Publication types

LinkOut - more resources